Best ETF Areas of Last Week
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 11 2024
0mins
Source: NASDAQ.COM
Wall Street Performance:
- S&P 500, Dow Jones, and Nasdaq Composite all saw gains last week due to easing inflation, soft manufacturing data, and a tech rally.
- Treasury yields declined, boosting the market rally, with technology stocks seeing significant inflows.
US Economy:
- The US economy added 272,000 jobs in May 2024, the highest in five months, surpassing forecasts and previous monthly gains.
Winning ETF Areas:
- Bitcoin Miners ETFs surged, reflecting confidence in potential Fed rate cuts.
- Natural Gas ETFs rose as natural gas maintains a critical role in U.S. electricity generation.
- Semiconductor ETFs performed well, driven by NVIDIA's growth in AI chips for data centers.
Weight-Loss Drugs:
- Weight loss drug manufacturers' shares increased, with expectations of a growing market due to rising obesity rates.
- Intense competition exists among companies producing GLP-1 medicines, seen as revolutionary in the pharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 45.760
Low
42.00
Averages
54.67
High
70.00
Current: 45.760
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk Q1 Earnings Preview Amidst Competitive Landscape
- Intensifying Market Competition: Novo Nordisk is set to report Q1 earnings on May 6, with consensus EPS at $1.10 and revenue at $11.26 billion, but three downward revisions in the past three months indicate increasing competitive pressure on its GLP-1 drug franchise.
- Strong Prescription Demand: Early demand for Novo's oral semaglutide (Wegovy) has been robust, with over 600,000 prescriptions written in the first two months, suggesting a potential outpacing of Eli Lilly's competing offerings in the market.
- Pricing Strategy Adjustments: In response to market pressures, Novo plans to cut U.S. list prices for Wegovy, Ozempic, and Rybelsus by approximately 35%-50%, aiming to expand market share and improve accessibility, although this may compress margins in the short term.
- Strategic Partnership Development: Novo's collaboration with Hims & Hers Health will see the platform offer Novo's branded GLP-1 drugs while discontinuing compounded alternatives, which could reduce gray-market competition and enhance Novo's brand positioning in the market.
See More
First Generic Versions of Ozempic Approved in Canada
- Generic Approval: Health Canada approved the first generic versions of Ozempic from Dr. Reddy's Laboratories on April 28, followed by another from Apotex, marking the beginning of increased market competition.
- Market Impact Assessment: Analyst Evan Seigerman noted that these new generics could lead to a decline in international revenue for semaglutide, although the impact on the U.S. market is expected to be limited due to competition from Eli Lilly's Mounjaro.
- Novo's Response Strategy: Emil Kongshøj Larsen, EVP of International Operations at Novo Nordisk, stated that the impact of generics is anticipated to be in the low single digits, highlighting the strong uptake of their savings card strategy in Canada.
- Pricing Policy Change: Canadian policy mandates a 65% price cut to Novo's list price once three generic competitors enter the market, which will significantly influence their future market strategy.
See More
Eli Lilly's Stock Surge and Competitor Analysis
- Eli Lilly's Strong Performance: Eli Lilly's GLP-1 weight loss drugs saw sales increase by 125% and 80% in Q1 2026, showcasing robust performance in a rapidly evolving pharmaceutical market, although its P/E ratio stands at 34x, above the industry average of 23x, indicating optimistic market expectations for future growth.
- Novo Nordisk Catching Up: Novo Nordisk's newly launched GLP-1 pill gained traction with 1.3 million prescriptions in the first quarter, suggesting a competitive edge in weight loss effectiveness, prompting the company to raise its full-year 2026 guidance and boosting market confidence.
- Pfizer's Challenges: Pfizer has yet to establish a foothold in the GLP-1 market after having to drop its drug candidate; however, it is actively acquiring promising candidates and advancing oncology and migraine drug development, maintaining its long-standing industry leadership.
- Market Sentiment Analysis: Wall Street's enthusiasm for Eli Lilly has inflated its valuation, prompting caution among long-term investors, while the undervaluation of Novo Nordisk and Pfizer may present greater upside potential, especially in light of overly pessimistic market sentiment.
See More
McDonald's Q1 Earnings Exceed Expectations
- McDonald's Strong Performance: McDonald's reported a 3.8% increase in global comparable sales for Q1, surpassing the 3.7% consensus estimate, driven by the introduction of the high-margin Big Arch burger and value offerings, thereby enhancing its competitive position in the fast-food market.
- Novo Nordisk Drug Launch: Novo Nordisk's oral diabetes medication Ozempic is now available for same-day delivery through Amazon's pharmacy, leading to a 0.83% stock increase, marking a significant advancement in digital distribution channels that could enhance its market share.
- Datadog Earnings Surge: Datadog's Q1 non-GAAP EPS jumped approximately 30% year-over-year to $0.60, with revenue climbing around 32% to about $1 billion, exceeding analyst expectations and resulting in a roughly 20% premarket stock surge, indicating strong market demand and positive company outlook.
- Papa John's Sales Decline: Papa John's reported a 7.7% drop in total revenue to $478.6 million in Q1, with North American comparable sales down 6.4%, despite a 3.6% growth in international operations, highlighting challenges the company faces in a competitive market.
See More
Amazon Launches Same-Day Delivery for Ozempic Pill
- Delivery Innovation: Amazon announced that its pharmacy division will offer same-day delivery for Novo Nordisk's newly launched Ozempic pill, available in nearly 3,000 U.S. cities, with plans to expand to 4,500 cities by the end of 2026, significantly enhancing patient access to medication.
- In-Office Service Enhancement: The Ozempic pill will be available at self-service kiosks in Amazon's One Medical clinics, allowing patients to pick up their medication within minutes after appointments, thereby improving the patient experience by eliminating long pharmacy wait times.
- Transparent Pricing: For insured patients, the monthly cost for the Ozempic pill starts at $25, while cash-paying customers can purchase the starting dose for $149, a pricing strategy aimed at attracting more patients and enhancing market competitiveness.
- Strategic Market Positioning: By partnering with Novo Nordisk, Amazon not only expands its pharmaceutical delivery services but also strengthens its position in the healthcare sector, showcasing its strategic vision in the rapidly growing digital health market.
See More
Eli Lilly's Dominance in the Anti-Obesity Drug Market
- Market Leadership: Eli Lilly began to dominate the anti-obesity drug market in 2025 due to stronger products and better execution, despite Novo Nordisk's previous leadership, indicating its significant share in a multi-billion dollar market.
- Significant Profitability: In Q1 2026, Lilly reported a net income of $7.4 billion, more than doubling year-over-year, primarily driven by rapid sales growth of its tirzepatide-based drugs, highlighting that its GLP-1 drug franchise is a key profitability driver.
- Production Capacity Expansion: Lilly has heavily invested in expanding production capacity, providing a structural advantage that smaller competitors cannot replicate, ensuring it can meet the strong demand for GLP-1 drugs in the future.
- Relative Investment Safety: Compared to smaller companies that rely on a single drug, Lilly's diversified pharmaceutical portfolio and strong cash flow demonstrate its relative safety and sustainable growth potential in the anti-obesity drug market.
See More
Novo Nordisk Q1 Earnings Preview Amidst Competitive Landscape
- Intensifying Market Competition: Novo Nordisk is set to report Q1 earnings on May 6, with consensus EPS at $1.10 and revenue at $11.26 billion, but three downward revisions in the past three months indicate increasing competitive pressure on its GLP-1 drug franchise.
- Strong Prescription Demand: Early demand for Novo's oral semaglutide (Wegovy) has been robust, with over 600,000 prescriptions written in the first two months, suggesting a potential outpacing of Eli Lilly's competing offerings in the market.
- Pricing Strategy Adjustments: In response to market pressures, Novo plans to cut U.S. list prices for Wegovy, Ozempic, and Rybelsus by approximately 35%-50%, aiming to expand market share and improve accessibility, although this may compress margins in the short term.
- Strategic Partnership Development: Novo's collaboration with Hims & Hers Health will see the platform offer Novo's branded GLP-1 drugs while discontinuing compounded alternatives, which could reduce gray-market competition and enhance Novo's brand positioning in the market.
See More
First Generic Versions of Ozempic Approved in Canada
- Generic Approval: Health Canada approved the first generic versions of Ozempic from Dr. Reddy's Laboratories on April 28, followed by another from Apotex, marking the beginning of increased market competition.
- Market Impact Assessment: Analyst Evan Seigerman noted that these new generics could lead to a decline in international revenue for semaglutide, although the impact on the U.S. market is expected to be limited due to competition from Eli Lilly's Mounjaro.
- Novo's Response Strategy: Emil Kongshøj Larsen, EVP of International Operations at Novo Nordisk, stated that the impact of generics is anticipated to be in the low single digits, highlighting the strong uptake of their savings card strategy in Canada.
- Pricing Policy Change: Canadian policy mandates a 65% price cut to Novo's list price once three generic competitors enter the market, which will significantly influence their future market strategy.
See More
Eli Lilly's Stock Surge and Competitor Analysis
- Eli Lilly's Strong Performance: Eli Lilly's GLP-1 weight loss drugs saw sales increase by 125% and 80% in Q1 2026, showcasing robust performance in a rapidly evolving pharmaceutical market, although its P/E ratio stands at 34x, above the industry average of 23x, indicating optimistic market expectations for future growth.
- Novo Nordisk Catching Up: Novo Nordisk's newly launched GLP-1 pill gained traction with 1.3 million prescriptions in the first quarter, suggesting a competitive edge in weight loss effectiveness, prompting the company to raise its full-year 2026 guidance and boosting market confidence.
- Pfizer's Challenges: Pfizer has yet to establish a foothold in the GLP-1 market after having to drop its drug candidate; however, it is actively acquiring promising candidates and advancing oncology and migraine drug development, maintaining its long-standing industry leadership.
- Market Sentiment Analysis: Wall Street's enthusiasm for Eli Lilly has inflated its valuation, prompting caution among long-term investors, while the undervaluation of Novo Nordisk and Pfizer may present greater upside potential, especially in light of overly pessimistic market sentiment.
See More
McDonald's Q1 Earnings Exceed Expectations
- McDonald's Strong Performance: McDonald's reported a 3.8% increase in global comparable sales for Q1, surpassing the 3.7% consensus estimate, driven by the introduction of the high-margin Big Arch burger and value offerings, thereby enhancing its competitive position in the fast-food market.
- Novo Nordisk Drug Launch: Novo Nordisk's oral diabetes medication Ozempic is now available for same-day delivery through Amazon's pharmacy, leading to a 0.83% stock increase, marking a significant advancement in digital distribution channels that could enhance its market share.
- Datadog Earnings Surge: Datadog's Q1 non-GAAP EPS jumped approximately 30% year-over-year to $0.60, with revenue climbing around 32% to about $1 billion, exceeding analyst expectations and resulting in a roughly 20% premarket stock surge, indicating strong market demand and positive company outlook.
- Papa John's Sales Decline: Papa John's reported a 7.7% drop in total revenue to $478.6 million in Q1, with North American comparable sales down 6.4%, despite a 3.6% growth in international operations, highlighting challenges the company faces in a competitive market.
See More
Amazon Launches Same-Day Delivery for Ozempic Pill
- Delivery Innovation: Amazon announced that its pharmacy division will offer same-day delivery for Novo Nordisk's newly launched Ozempic pill, available in nearly 3,000 U.S. cities, with plans to expand to 4,500 cities by the end of 2026, significantly enhancing patient access to medication.
- In-Office Service Enhancement: The Ozempic pill will be available at self-service kiosks in Amazon's One Medical clinics, allowing patients to pick up their medication within minutes after appointments, thereby improving the patient experience by eliminating long pharmacy wait times.
- Transparent Pricing: For insured patients, the monthly cost for the Ozempic pill starts at $25, while cash-paying customers can purchase the starting dose for $149, a pricing strategy aimed at attracting more patients and enhancing market competitiveness.
- Strategic Market Positioning: By partnering with Novo Nordisk, Amazon not only expands its pharmaceutical delivery services but also strengthens its position in the healthcare sector, showcasing its strategic vision in the rapidly growing digital health market.
See More
Eli Lilly's Dominance in the Anti-Obesity Drug Market
- Market Leadership: Eli Lilly began to dominate the anti-obesity drug market in 2025 due to stronger products and better execution, despite Novo Nordisk's previous leadership, indicating its significant share in a multi-billion dollar market.
- Significant Profitability: In Q1 2026, Lilly reported a net income of $7.4 billion, more than doubling year-over-year, primarily driven by rapid sales growth of its tirzepatide-based drugs, highlighting that its GLP-1 drug franchise is a key profitability driver.
- Production Capacity Expansion: Lilly has heavily invested in expanding production capacity, providing a structural advantage that smaller competitors cannot replicate, ensuring it can meet the strong demand for GLP-1 drugs in the future.
- Relative Investment Safety: Compared to smaller companies that rely on a single drug, Lilly's diversified pharmaceutical portfolio and strong cash flow demonstrate its relative safety and sustainable growth potential in the anti-obesity drug market.
See More
